These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 31883112

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.
    Khalil A, Würthwein G, Golitsch J, Hempel G, Fobker M, Gerss J, Möricke A, Zimmermann M, Smisek P, Zucchetti M, Nath C, Attarbaschi A, Von Stackelberg A, Gökbuget N, Rizzari C, Conter V, Schrappe M, Boos J, Lanvers-Kaminsky C.
    Haematologica; 2022 Jan 01; 107(1):49-57. PubMed ID: 33299233
    [Abstract] [Full Text] [Related]

  • 6. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB.
    Lancet Oncol; 2015 Dec 01; 16(16):1677-90. PubMed ID: 26549586
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI.
    Clin Cancer Res; 2004 Aug 15; 10(16):5335-41. PubMed ID: 15328169
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
    Tong WH, van der Sluis IM, Alleman CJ, van Litsenburg RR, Kaspers GJ, Pieters R, Uyl-de Groot CA.
    Haematologica; 2013 May 15; 98(5):753-9. PubMed ID: 23403311
    [Abstract] [Full Text] [Related]

  • 11. Pegasparaginase: where do we stand?
    Zeidan A, Wang ES, Wetzler M.
    Expert Opin Biol Ther; 2009 Jan 15; 9(1):111-9. PubMed ID: 19063697
    [Abstract] [Full Text] [Related]

  • 12. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
    Tram Henriksen L, Gottschalk Højfeldt S, Schmiegelow K, Frandsen TL, Skov Wehner P, Schrøder H, Klug Albertsen B, Nordic Society of Pediatric Hematology and Oncology, NOPHO Group.
    Pediatr Blood Cancer; 2017 Dec 15; 64(12):. PubMed ID: 28660740
    [Abstract] [Full Text] [Related]

  • 13. Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach.
    Siebel C, Lanvers-Kaminsky C, Alten J, Smisek P, Nath CE, Rizzari C, Boos J, Würthwein G.
    Eur J Drug Metab Pharmacokinet; 2022 Mar 15; 47(2):187-198. PubMed ID: 34878584
    [Abstract] [Full Text] [Related]

  • 14. Depletion of d- and l-asparagine in cerebrospinal fluid in acute lymphoblastic leukemia during PEGasparaginase therapy.
    Brigitha LJ, Pieters R, Struys EA, Bakkali A, van der Sluis IM.
    Pediatr Blood Cancer; 2022 Nov 15; 69(11):e29865. PubMed ID: 35880973
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
    Hak LJ, Relling MV, Cheng C, Pei D, Wang B, Sandlund JT, Rubnitz J, Pui CH.
    Leukemia; 2004 Jun 15; 18(6):1072-7. PubMed ID: 15057247
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model.
    Kloos RQH, Mathôt R, Pieters R, van der Sluis IM.
    Haematologica; 2021 May 01; 106(5):1254-1261. PubMed ID: 32327497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.